Corpus Intelligence IC Memo — HOSPITAL METRO HATO REY INC. 2026-04-26 06:38 UTC
IC Memo — HOSPITAL METRO HATO REY INC.
Investment Committee Memorandum | PR | 84 beds | Grade D | EBITDA uplift $2.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

HOSPITAL METRO HATO REY INC.

CCN 400128 | HATO REY, PR | 84 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

HOSPITAL METRO HATO REY INC. is a 84-bed safety-net/medicaid heavy in HATO REY, PR with $34.2M in net patient revenue and a -18.8% operating margin. The hospital serves a payer mix of 5.2% Medicare, 25.7% Medicaid, and 69.1% commercial.

Thesis: Turnaround. Our ML models identify $2.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -18.8% to -11.4% (+736bps).

Net Revenue HCRIS$34.2M
Current EBITDA COMPUTED$-6.4M
Operating Margin COMPUTED-18.8%
Occupancy HCRIS33.9%
Revenue / Bed COMPUTED$407K
Net-to-Gross HCRIS57.4%
Distress Probability ML60.3%

2. Market Context & Competitive Position

61
PR Hospitals
-8.8%
State Median Margin
38
Comparable Hospitals

PR has 61 Medicare-certified hospitals with a median operating margin of -8.8%. The target's margin of -18.8% places it below the state median. Among 38 size-comparable peers (42-168 beds), the median margin is -9.4%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (42-168), prioritizing same-state peers. 38 hospitals in the comp set.

HospitalStateBedsRevenueMargin
HOSPITAL METRO HATO REY INC. (Target)PR84$34.2M-18.8%
ADMIN DE SERVICIOS MEDICOS DE PR65$179.7M-50.0%
HOSPITAL PAVIA SANTURCEPR156$101.9M-9.4%
HOSPITAL MENONITA AIBONITOPR129$92.1M-3.1%
HOSPITAL DE LA CONCEPCIONPR167$91.0M-3.9%
CORPORACION DEL CENTRO CARDIOVPR164$77.2M-14.2%
HOSPITAL MENONITA GUAYAMAPR134$73.2M19.4%
ASHFORD PRESBYTERIAN COMMUNITYPR152$63.5M-13.8%
HOSPITAL DAMASPR128$59.6M-21.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$719K+210bp18mo
Cost to Collect4.5%2.5%$685K+200bp12mo
Denial Rate Reduction12.0%6.5%$678K+198bp12mo
A/R Days Reduction5200.0%3800.0%$416K+122bp9mo
Clean Claim Rate88.0%96.0%$22K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$719K
Cost to Collect
$685K
Denial Rate Reduction
$678K
A/R Days Reduction
$416K
Clean Claim Rate
$22K
Total EBITDA Uplift$2.5M
Current EBITDA$-6.4M
+ RCM Uplift+$2.5M
Pro Forma EBITDA$-3.9M
Current Margin-18.8%
Pro Forma Margin-11.4%
WC Released (1x)$1.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-9.9M$-17.2M0.00x-100.0%
Base (11x exit)10.0x11.0x$-9.9M$-22.1M0.00x-100.0%
Bull Case9.0x11.0x$-8.9M$-17.0M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-8.9M$-21.2M0.00x-100.0%
Bear Case11.0x10.0x$-10.9M$-26.6M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-10.9M$-32.7M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumElevated Medicaid exposure (25.7%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
MediumLow occupancyAt 33.9%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 60.3% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 38 hospitals with 42-168 beds
  • Same-state prioritization (n=39)
  • Comp margins: P25=-21.0% / P50=-9.4% / P75=-2.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.